Sickle Cell in Focus

Transcription

1 PROGRAMME DIRECTORS Swee Lay Thein / John Tisdale National Heart, Lung and Blood Institute, National Institutes of Health, USA BOOK ONLINE NOW See back page for mor information The 9th Sickle Cell in Focus JUNE 2015, LONDON Conference EHA-CME accreditation in progress The LIght at EUSTON friends house euston road london, nw1 2bj a t w o -day, i n t e n s i v e e d u c at i o n a l c o n f e r e n c e o n c u r r e n t a n d e m e r g i n g c l i n i c a l c o m p l i c at i o n s a n d m a n a g e m e n t o f s i c k l e c e l l d i s e a s e p l u s, s e s s i o n s o n d r u g d e v e l o p m e n t, c l i n i c a l t r i a l s a n d new genetics f o r c o n s u lta n t s, t r a i n e e d o c t o r s, h e a lt h p r o f e s s i o n a l s i n v o lv e d in t h e c a r e o f pat i e n t s w i t h t h e d i s e a s e, a n d a c a d e m i c researchers in this field

2 Monday 15 JUNE The Euston session one 09:00am 09:10am 09:40am 10:10am Welcome Sickle cell disease: a global health issue Kwaku Ohene-Frempong, Children s Hospital of Philadelphia / University of Pennsylvania, USA Evolution of sickle cell disease where are we now? Swee Lay Thein, National Heart, Lung and Blood Institute, National Institutes of Health, USA How I treat: Cerebrovascular disease - Paediatrics David Rees, King s College London / King s College Hospital NHS Foundation Trust, UK - Adults Paul Holmes, Guy s & St. Thomas NHS Foundation Trust, UK 11:00am session two 11:30am Drug development and clinical trials (part I): - Insights into Pathophysiology and therapeutic targets Bart Biemond, Academic Medical Center, University of Amsterdam, Netherlands - Drug development for a complex disease Susan Perrine, Howard s University Hospital, Washington DC, USA 12:30pm Lunch

3 Monday 15 JUNE session three 1:30pm How I treat: - Avascular necrosis Marcus Bankes, Guy s & St. Thomas NHS Foundation Trust, UK - Sickle hepatopathy Pauline Kane / Abid Suddle, King s College Hospital NHS Foundation Trust, UK - Reproductive issues in sickle cell disease Andra James, Duke University, USA 3:00pm session FOUR 3:30pm Debate: all patients with sickle cell disease should be on hydroxyurea therapy - Yes: Russell Ware, Cincinnati Children s Hospital, USA - No: Miguel Abboud, American University of Beirut Medical Center, Lebanon 5:00pm Day one close (Please note: all details are subject to change at short notice)

4 TUEsDAy 16 JUNE The Euston session one 09:00am 09:10am Welcome Drug development and clinical trials (part II) - Targeting HbS polymerisation Yogen Saunthararajah, Cleveland Clinic, USA - Targeting cell adhesion/ vaso-occlusion/vasoculopathy Deepa Manwani, The Children s Hospital at Montefiore, New York, USA 10:10am How I treat: Transfusion reactions Alek Mijovic, King s College Hospital NHS Foundation Trust, UK 10:35am session two 11:05pm How I treat: - Iron overload John Porter, University College London, UK - Sickle pain i) New concepts Jim Taylor, National Heart, Lung and Blood Institute, National Institutes of Health, USA ii) Management Samir Ballas, Thomas Jefferson University, USA 12:20pm Lunch

5 TUEsDAy 16 JUNE SESSION THREE 1:20pm Revisiting haemolysis in sickle cell disease - A role for haemolysis in the pathophysiology and clinical manifestations of sickle cell disease Alan Schechter, National Institute of Diabetes and Digestive and Kidney Diseases / National Institutes of Health, USA - Cell free haemoglobin and its scavenger proteins: Dominik J. Schaer, University of Zurich, Switzerland - Targeting the anaemia and dealing with the effects of the haemolysis Lucia de Franceschi, Università degli studi di Verona, Italy 2:35pm session FOUR 3:00pm Sickle cell disease: attempting a cure - Bone marrow transplant who, when and how? Josu de la Fuente, Imperial College London, UK - New genetics to the rescue: i) Gene therapy John Tisdale, National Heart, Lung and Blood Institute, National Institutes of Health, USA ii) Genome editing for disease correction Stefano Rivella, Weill Cornell Medical College, New York, USA iii) When all fails, prevention is better than disease limitation Barnaby Clark, King s College London / King s College Hospital NHS Foundation Trust, UK 5:00pm Close of conference (Please note: all details are subject to change at short notice)

6 VENUE INFORMATION Located directly opposite London s Euston Station, The Light offers beautiful, contemporary facilities in an easily accesible location. We hope you will enjoy this fantastic, new London location for Sickle Cell in Focus! contacts UK Annabelle Kelly E: belle.kelly@kcl.ac.uk T: (0) USA Karen Kendrick E: kendrickk@nhlbi.nih.gov T: BOOK YOUR PLACE ONLINE via the King s College London estore: Conference Fees*: Industry: 550 Consulants / Academics / Charity Sector: 350 Students / Trainees: 175 *Please note: there is no one-day rate available and all fees are non-refundable less than 30 days before the event.; the fee covers entry to SCiF and refreshments throughout the conference only; all other expenses such as travel and accommodation are not included and must be organised by you; name changes are also not permitted. Closing date for all bookings is 10th June (Please note: all details are subject to change at short notice)